IDH1 and non-small cell lung carcinoma: In this study with nearly 2000 NSCLC specimens, we confirmed a low incidence of IDH1/2 mutations (0.5%), similar to those reported from MSK‐IMPACT (0.4%) and The Cancer Genome Atlas (TCGA) (0.4%) and relatively lower than that reported by Toth, et al (1.1%).12, 13, 14